Latest Breaking News On - Oncocyte corporation - Page 1 : comparemela.com

StockNews com Begins Coverage on OncoCyte (NASDAQ:OCX)

Analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock. Several other brokerages have also issued reports on OCX. Stephens reiterated an “equal weight” rating and issued a $4.00 price target on shares […]

United statesAndrew arnoNeedham companyOncocyte corporationSecurities exchange commissionGet free reportBroadwood partnersExchange commissionDirector andrew arnoCyte corporationOncocyte daily

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJosh riggsEkke schuetzKlemens buddeJulia beckJeff ramsonKatharina mayerExchange commissionOncocyte corporation nasdaqUniversity of viennaAmerican transplant congress onOncocyte corporationOncocyte vitagraft kidney study results publishedNew england journalAmerican transplant congressEngland journal

Favorable Oncocyte Vitagraft Kidney Study Results Published In The New England Journal Of Medicine

Favorable Oncocyte Vitagraft Kidney Study Results Published In The New England Journal Of Medicine
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesJeff ramsonGeorg boVitagraft liverEkke schuetzKlemens buddeJulia beckJosh riggsVitagraft kidneyKatharina mayerUniversity of viennaOncocyte corporationAmerican transplant congress onOncocyte corporation nasdaqExchange commissionAmerican transplant

OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the stock. Several other brokerages have also recently weighed in on OCX. Needham & Company LLC reiterated a buy rating and issued a $4.25 price objective on shares of OncoCyte […]

United statesAndrew arnoOncocyte corporationNeedham companySecurities exchange commissionOncocyte company profileFree reportDirector andrew arnoExchange commissionBroadwood partnersGet free reportCyte corporationOncocyte daily

StockNews com Begins Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the stock. A number of other research firms have also recently commented on OCX. Benchmark restated a speculative buy rating and issued a $5.00 price objective on shares of OncoCyte […]

United statesAndrew arnoOncocyte corporationNeedham companyFree reportDirector andrew arnoBroadwood partnersGet free reportCyte corporationOncocyte daily